Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The administration of Calcifediol in patients with COVID-19, will reduce the development of
SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU
admission and death from the process, reducing days of hospitalization, facilitating the
recovery of the same, acting significantly and positively, in any of its phases throughout
the natural history of illness.
As a treatment with extensive experience of clinical use, safe, inexpensive, and potentially
very effective, it will have a highly efficient cost-benefit impact on the prevention of
SARS.
Phase:
Phase 2
Details
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba
Collaborators:
Dynamic Solutions FAES Farma Faes Farma, S.A. Junta de Andalucía - Consejería de Salud y Familias, Spain